FTH, US81728A2078

Faeth Therapeutics stock faces a year end PIKTOR test

Published on 10/07/2026 at 06:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Faeth Therapeutics stock was last at USD 26.89 on October 6, 2026, as PIKTOR approached a year-end Phase 2 data milestone. Q2 net loss reached USD 16.0 million.

FTH, US81728A2078, Illustration mit AI erstellt.

Faeth Therapeutics stock (ISIN US81728A2078) was last at USD 26.89 on Nasdaq on October 6, 2026, while the company placed its PIKTOR cancer program ahead of a year-end clinical milestone. According to Faeth Therapeutics, the October 6 KOL event covered PIKTOR's multi-node approach to the PI3K/AKT/mTOR pathway and the upcoming Phase 2 readout in endometrial cancer.

PIKTOR reaches a key test

PIKTOR combines serabelisib, a PI3K-alpha inhibitor, with sapanisertib, an mTORC1/mTORC2 inhibitor. The company is studying the investigational oral combination in second-line advanced endometrial cancer through Study FTH-PIK-201.

Faeth Therapeutics said on September 8, 2026, that topline Phase 2 data were anticipated by year-end 2026. The same release describes a separate Phase 1b/2 breast cancer program, with interim data anticipated in 2027.

Losses underline the clinical risk

The financial backdrop remains demanding. According to RTTNews on September 9, 2026, Faeth posted a USD 16.0 million net loss for the second quarter of 2026, compared with USD 4.9 million a year earlier. That comparison puts the upcoming clinical readout ahead of a business model that is still dependent on development progress rather than product revenue.

Market expectations are more constructive. A three-analyst consensus published by Tiblio carries a Strong Buy rating and an average price target of USD 56.67. TradingView lists a USD 46.00 minimum and USD 70.00 maximum target, giving the consensus a wide spread around the clinical catalyst.

FTH remains below its yearly high

FTH traded with a USD 26.00 intraday low and a USD 29.60 high on October 6, 2026, with volume of 289,149 shares. Its USD 693.2 million market capitalization and USD 26.89 last price place the stock below the USD 42.14 52-week high and above the USD 7.45 low.

Faeth Therapeutics stock was last at USD 26.89 on Nasdaq on October 6, 2026. The next material valuation test is tied to the timing and quality of the PIKTOR Phase 2 data rather than current revenue.